Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Editas_Medicine> ?p ?o }
Showing triples 1 to 36 of
36
with 100 triples per page.
- Editas_Medicine abstract "Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. The company went public on 2 Feb 2016. This initial public offering was noted as being the first such from a company which aims to use \"DNA itself to internally treat afflictions\". The company has conceded that “It will be many years, if ever, before we have a product candidate ready for commercialization.” Further, the company's valuation depends on a single patent, which holder was in dispute as of early 2016, presenting a major risk to the company's continued viability.The company entered into a strategic collaboration with Juno Therapeutics in 2015 to combine its CRISPR-Cas9 technology with Juno's experience in creating chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics.Direct competitors to Editas include Crispr Therapeutics, Intellia Therapeutics, and Caribou Biosciences.".
- Editas_Medicine country United_States.
- Editas_Medicine wikiPageID "49392319".
- Editas_Medicine wikiPageLength "2201".
- Editas_Medicine wikiPageOutDegree "12".
- Editas_Medicine wikiPageRevisionID "707476432".
- Editas_Medicine wikiPageWikiLink CRISPR.
- Editas_Medicine wikiPageWikiLink Cambridge,_Massachusetts.
- Editas_Medicine wikiPageWikiLink Category:Companies_based_in_Cambridge,_Massachusetts.
- Editas_Medicine wikiPageWikiLink Category:Pharmaceutical_companies_of_the_United_States.
- Editas_Medicine wikiPageWikiLink Chimeric_antigen_receptor.
- Editas_Medicine wikiPageWikiLink Genome_editing.
- Editas_Medicine wikiPageWikiLink Initial_public_offering.
- Editas_Medicine wikiPageWikiLink Juno_Therapeutics.
- Editas_Medicine wikiPageWikiLink Patent_infringement.
- Editas_Medicine wikiPageWikiLink Pharmaceutical_industry.
- Editas_Medicine wikiPageWikiLink T_cell_receptor.
- Editas_Medicine wikiPageWikiLinkText "Editas Medicine".
- Editas_Medicine wikiPageWikiLinkText "Editas".
- Editas_Medicine wikiPageUsesTemplate Template:Reflist.
- Editas_Medicine wikiPageUsesTemplate Template:US-company-stub.
- Editas_Medicine subject Category:Companies_based_in_Cambridge,_Massachusetts.
- Editas_Medicine subject Category:Pharmaceutical_companies_of_the_United_States.
- Editas_Medicine hypernym Company.
- Editas_Medicine type Agent.
- Editas_Medicine type Company.
- Editas_Medicine type Organisation.
- Editas_Medicine type Organization.
- Editas_Medicine type Agent.
- Editas_Medicine type SocialPerson.
- Editas_Medicine type Thing.
- Editas_Medicine type Q43229.
- Editas_Medicine comment "Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. The company went public on 2 Feb 2016. This initial public offering was noted as being the first such from a company which aims to use \"DNA itself to internally treat afflictions\".".
- Editas_Medicine label "Editas Medicine".
- Editas_Medicine wasDerivedFrom Editas_Medicine?oldid=707476432.
- Editas_Medicine isPrimaryTopicOf Editas_Medicine.